Abstract Chronic obstructive pulmonary disease (COPD) is an increasing public health problem, generating considerable costs. The objective of this study was to identify factors affecting COPD-related costs. A cohort of 179 subjects with COPD was interviewed over the telephone on four occasions about their annual use of COPD-related resources. The data set and explanatory variables were analysed by means of multivariate regression techniques for six different types of cost: societal (or total), direct (health care) and indirect (productivity), and three subcomponents of direct costs-hospitalisation, outpatient and medication. Poor lung function, dyspnoea and asthma were independently associated with higher costs. Poor lung function (severity of COPD) significantly increased all six examined cost types. Dyspnoea (breathing problems) also increased costs, though to a varying extent. The presence of reported asthma increased total, direct, outpatient and medication costs. Poor lung function and, to a lesser extent, extent of dyspnoea and concomitant asthma, were all strongly associated with higher COPD-related costs. Strong efforts should be made to prevent the progression of COPD and its symptoms.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major public health problem. In 1990 it was ranked as the 12th leading cause of disability-adjusted life-years (DALYs) lost and, according to projections, it will become the 5th such cause in 2020 [1] . COPD is also a costly disease, generating considerable health-care costs as well as indirect costs in terms of lost productivity from days off work, early retirement and death caused by disease [2] [3] [4] [5] [6] .
Previous research has identified several risk factors that affect the costs of COPD. For example, Crocket et al. [7] showed a dependency between comorbidity and length of stay in hospital. Poor self-reported health status and health-related quality of life (QoL) have been shown to increase resource utilisation [6, 8] . In addition, poor lung function affects health-care utilisation [3, [9] [10] [11] . However, few studies with detailed multivariate analysis of COPD costs have been carried out [12] . As COPD is a complex disease with multiple facets it is essential to take into account the effect on costs of a number of potentially influencing factors rather than focussing on one individual background factor at a time, as has been done in previous research.
The objective of this study was to identify factors influencing COPD costs in Swedish society by means of multivariate analysis. From a policy standpoint, it is important to identify different risk factors and cost drivers in society and, if possible, to work proactively to influence these. We have also corrected for other confounding factors (e.g. age, gender). We analysed factors potentially influencing societal (total), direct (health care) and indirect (productivity loss) costs; the direct costs were further subdivided into hospitalisation, outpatient care (specialist, GP, nurse and home visits) and medication costs, as different factors may influence different types of costs and may be important to different payers and thus relevant from different perspectives.
Patients and methods

Study sample
The study sample was derived from the obstructive lung disease in Northern Sweden (OLIN) studies, i.e. large-scale studies on the epidemiology of COPD, asthma and type-1 allergy in Northern Sweden which started in 1985 [13, 14] . Today, longitudinal studies of a number of cohorts are underway, including a total of approximately 40,000 children, adults, and elderly persons. The first survey of the second cohort of the OLIN studies included pulmonary function tests performed from 1993 to 1995 on 1,900 subjects born in 1925-1926, 1940-1941, 1955-1956 and 1970-1971 . The third survey of the first cohort of the OLIN studies was performed in 1996-1998 and included lung function tests performed on 2,600 subjects in three age cohorts: persons born in 1919-1920, 1934-1935 and 1949-1950 . The study cohort in the current study was derived from these two surveys and comprised subjects classified as having COPD.
COPD was defined according to the criteria of the British Thoracic Society [BTS; 15], which divide COPD into mild, moderate and severe disease. In addition, persons with a post-bronchodilator FEV 1 /VC ratio \70% (ratio of forced expiratory volume in 1 s and vital capacity) and FEV 1 C80% of the predicted value, which corresponds to the GOLD criteria for mild COPD [16] , were included in the study. These individuals are most commonly not diagnosed in clinical practice and are thus generally lowcost patients, but because of their high prevalence they account for a substantial proportion of the total societal costs of COPD [3] . Subjects with chronic airway obstruction who referred to themselves as asthmatics were also included in the OLIN studies, which is supported by the BTS guidelines [15] . Subjects with other diseases that explained their impaired pulmonary function were excluded. The study sample and methods have been described in detail previously [3, 11] .
Of 261 selected subjects, 212 individuals agreed to be interviewed about resource utilisation on four occasions in the course of a year. A structured telephone interview, using a specially designed and pilot-tested questionnaire, was conducted by one of the authors (S.-A. J.). To minimise potential recall bias, the patients kept daily diaries of resource use. The trained interviewer discussed these in detail with the interviewee on each occasion. We verified costly hospitalisations through hospital records. The 49 persons in the original study sample who did not take part in the study did not differ from the 212 participating subjects in terms of age, gender, smoking habits, area of residence or FEV 1 [3, 11] .
Costs
Societal COPD-related costs were divided into direct and indirect costs at 2004 values [exchange rate in May 2008: Swedish Krona (SEK) 1 = US $ 0.168, € 0.108). The direct costs included costs for hospitalisation, medication, health-care visits and contacts, oxygen therapy, equipment aids, moving to new quarters, home adaptations, and education or an occupational change. The indirect costs included absence from work, either short-or long-term. The sample was considered too small to include costs due to mortality. For a more detailed description on how the unit costs were estimated, please see Jansson et al. [3] and Andersson et al. [11] .
Regression analysis
Univariate and multiple linear regression analysis were performed to investigate the effects of different factors on COPD costs. These effects were analysed by the following definitions of costs: total costs (model 1), direct costs (model 2), indirect costs (model 3), hospitalisation costs (model 4), outpatient care costs (model 5) and medication costs (model 6). All tests of statistical significance were carried out at the 5% level, with 95% confidence intervals (CI) in the multiple analyses.
A test battery was applied to check for key properties of the regression models: White's test for homoscedasticity in the error distribution, the Jarque-Bera asymptotic test for normality, and the Ramsey regression specification error test (RESET) for omitted variables [17] [18] [19] . We also calculated the variance inflation factors (VIFs) to look for problems of multi-colinearity of the right-hand-side variables.
The sensitivity analysis employed (1) estimation techniques, (2) samples in which outliers defined by standardised residuals whose absolute values were higher than 1.96 were excluded, and (3) model specification.
The regression model was pre-defined as follows: All potential factors were expected to affect each of the six studied cost types to some extent, hence all ten were included in all analyses.
The initial data set included 212 persons with COPD. Complete data were obtained for 179 observations as some observations were missing for population density, employment and smoking. Table 1 gives the summary statistics for each of the variables used in the regression. There were no significant differences between the discarded observations and the final sample of 179. Table 2 presents the univariate analysis of all explanatory variables in relation to the six dependent variables. The variables with most significant correlations with the six cost types were severe COPD (FEV 1 \ 40%), presence of asthma and dyspnoea score 5. Tables 3 and 4 present the six multivariate analyses. The results differed slightly compared to those of univariate analysis. Severe COPD (FEV 1 \ 40% of predicted) significantly increased all six cost types. In all cases, individuals with severe COPD had much higher total costs than those with very mild COPD (P values ranging from \0.001 to \0.05). Moderate COPD (FEV 1 40-59%) increased total, indirect and medication costs, while mild COPD (FEV 1 60-79%) had a significant effect only on medication costs compared to subjects with very mild COPD (baseline category).
Results
Factors affecting COPD costs 219
Individuals with a higher degree of dyspnoea symptoms generally presented with higher costs, except for indirect costs (model 3). The presence of asthma raised total costs through direct, outpatient and medication costs (models 1-2, 5-6). The increase in direct costs for those with a disability pension reflected mainly higher medication costs (models 2, 6). Patients in the age group 64-69 years had lower medication consumption (model 6), whereas people living in areas with the highest population density consumed more medication (model 6). The very elderly and unemployed had lower indirect costs, as expected (model 3).
Gender, other comorbidities and pack-years had no significant effect on any of the cost types. This will be further elaborated on in the ''Discussion''.
Health-related QoL and its relation to costs was analysed via EQ-VAS and SGRQ (St George's Respiratory Questionnaire) [21, 22] . The generic instrument EQ-VAS not significant in any of the cases tested (models 1-6). In contrast, the disease-specific instrument SGRQ was strongly significant (P \ 0.001 for total costs), indicating that poor QoL was correlated with higher costs (data not shown). QoL was also strongly correlated with the dyspnoea variables. Because of missing values these two QoL variables reduced the sample size by a further 25% and they were therefore excluded from further analysis.
Methodological considerations and sensitivity analysis
The null hypothesis of normality in the error terms and the RESET test of no functional form misspecification were rejected in some of the models (see bottom rows of Tables 3, 4 ). This may be attributable to the exclusion of relevant variables or the use of an inappropriate functional form. However, it may also be attributable to the fact that the linear regression assumes that the dependent variable was unlimited and continuous, whereas our cost variables had a lower limit of zero. If a massive weight is located at zero, then this characteristic may destroy the linearity assumption and the estimates will be biassed. VIF and tolerance statistics were also calculated. These statistics provide measures of multicolinearity for the right-handside variables in the models. A general rule of thumb is that a VIF in excess of 20 (or a tolerance of less than 0.05) may merit further investigation. In our case the mean VIF was 2.16 and in no case higher than 5.53 (the tolerance statistic is 0.18), so we assumed that multicolinearity is not a serious problem.
The results reported in Tables 3 and 4 are remarkably robust to changes in the model specification and data. We excluded observations with standardised residuals whose absolute values were higher than 1.96 in the total cost model. By this criterion, seven observations (3.9% of the sample) were deleted. The total cost equation was then reanalysed and the results were about the same as in Table 3 .
As smoking is the main cause of COPD, we tested a number of smoking-related variables in addition to packyears (age when started smoking, current or ex-smoker, a proxy for the 9th deciles of high smokers), but none of these changed the overall results.
Discussion
COPD is a complex disease. From a policy standpoint, it is important to identify different risk factors and cost drivers and to work proactively to influence these, if possible. The objective of this study was to analyse the factors driving COPD costs in Sweden by means of multivariate techniques. The analysis was based on a data set consisting of 179 subjects, a representative cohort of subjects with COPD in Sweden [3, 11] . Poor lung function (as measured by FEV 1 ) significantly increased all six cost types. Disease severity, most commonly diagnosed by clinical FEV 1 measurements but also self-reported, has previously been reported as having strong links with resource use and costs [3, 23] . Hence, the results were very much as expected. What stands out is the fact that two of the variables contribute even further and thus we arrive at an even better prediction of patient costs.
Perhaps the most interesting finding of this study is the fact that severe dyspnoea leads to even higher costs, taking into account the already strong influence of disease severity measured by FEV 1 . Dyspnoea was also highly correlated with QoL and, when the disease-specific instrument SGRQ was included, dyspnoea variables turned out to be nonsignificant.
The positive correlation between self-reported asthma and high total costs of COPD appears to arise through outpatient care and medication costs. Patients with COPD may also have an asthma component. Others with COPD prefer to label themselves as asthmatics, or may even have been incorrectly classified as having asthma by the healthcare system, as many persons with COPD are diagnosed as having asthma. Several medications, such as inhaled glucocorticosteroids and bronchodilators, are used to treat [17] b The normality test is the Jarque-Bera asymptotic test [18] c The RESET test uses as auxiliary variables the predicted values of the regression estimates raised to polynomials of the third order [19] both diseases. This might be the reason why persons with COPD who also reported that they had asthma use more medication [3] . The fact that hospitalisation costs do not increase could be a sign that a possible asthma component is well controlled. The results relating to the variables disability pension and population density were also interesting. Individuals with a disability pension tend to consume more health-care resources and hence cost more. There may be a three-way link with age and comorbidity, which drives costs. Medication costs were increased by population density. It is, however, well known that closeness to health-care drives costs [24, 25] . The medication model is also the one with the best explanatory power.
Three variables-other comorbidity, gender and packyears-had no significant effect on any of the cost types.
About 62% of the sample presented with concomitant disease(s). Recent studies point to the close relationship of cardiovascular disease and COPD [26] . In a survey of seven countries, Wouters [23] found that patients with comorbidity generated up to double the COPD-related costs compared to COPD patients without comorbidity. In our sample, however, we lack exact information as to what the concomitant diseases were (except asthma) and how many there were. These other diagnoses (except asthma) are also self-reported and hence not clinically validated. For males, expenditure in other disease areas has been shown to be higher, although this could not be confirmed here. Wouters [23] did not find a consistent pattern for gender in COPD. Strassels [6] reported that women consumed more COPD resources than men. Finally, one would expect higher costs for those who have consumed more tobacco over their life span. It is well known that smoking is related to COPD itself and also to COPD severity [13] . As many as 83% of our sample was either current or ex-smokers. However, Strassels [6] found no relationship between tobacco exposure and resource consumption either. The explanation may be that there is a selection bias in that those high consumers of tobacco that remain alive are the ''healthy'' ones (a so-called survival effect). It appears that FEV 1 and dyspnoea are on the causal pathway somewhere between smoking and costs.
To the best of our knowledge, no previous study has addressed the same research question as highlighted here, i.e. factors influencing total COPD costs, split by various cost components. The few related studies that have been performed used varying models, methods, focus, patient samples, settings, cost components and endpoints. As a consequence, the results have been rather mixed, as can be seen in Table 5 .
In the univariate analyses QoL, lung function and comorbidity seem to influence admissions and resource use in COPD [3, [6] [7] [8] [9] [10] [11] . As for the multivariate analyses, Mapel et al. [27] tried to identify the clinical factors that were most predictive of increased direct medical costs in a COPD population consisting of 2,116 subjects. Severity of airflow obstruction was a significant but weak predictor. Prior hospitalisation, home oxygen use, the presence of comorbid conditions and symptoms of dyspnoea were better predictors of direct medical costs.
Garcia-Aymerich et al. [28] studied potential risk factors of exacerbations and admissions for COPD exacerbations in 86 subjects. Three or more COPD admissions in the previous year, FEV 1 , under prescription of longterm oxygen therapy and current smoking were all significant risk factors for COPD hospitalisation. Decramer et al. [29] examined the utilisation of healthcare resources in 57 patients with moderate to severe COPD. They concluded that utilisation of health-care resources in patients with COPD was related to ventilatory and peripheral muscle strength. Kessler et al. [30] looked at the predictive factors of hospitalisation for acute exacerbation in 64 patients with moderate to severe COPD. The significant risk factors identified were low body mass index (BMI), limited ability to walk, and a few clinical measurements (increased gas exchange impairment, pulmonary haemodynamic worsening and mean pulmonary artery pressure). Finally, Oostenbrink and Rutten-van Mölken [31] sought to identify risk factors for hospitalisation in 519 COPD patients. Underweight (BMI \ 18.5), history of concomitant diseases and increased dyspnoea were the risk factors identified. As can be seen, some of the identified risk factors for hospitalisation and healthcare resource use overlap with the risk factors in the present study. Furthermore, some or all the studies above found no or mixed relationships to hospitalisation and health-care resource use for variables such as age, gender, comorbidity and smoking habits-variables also found to be non-significant in this study. Some preliminary policy conclusions may be drawn from our analysis. First, the three most important cost drivers are all health-related. Thus, early detection through screening and prevention initiatives in high-risk individuals has the potential to be very cost-effective. Patients with COPD who have severe dyspnoea symptoms and poor lung function have costs several times higher than those with COPD who have milder dyspnoea symptoms and better lung function. Early diagnosis followed by active interventions aimed at delaying disease progression (e.g. preventive measures such as quitting smoking, early initiation of glucocorticosteroids in suspected asthmatics, etc.) may reduce resource use such as for hospitalisation and outpatient care and medication in the long run [32] . Second, people living in more populated areas tend to use more medication, although hospitalisation costs and/or the costs of outpatient care in these areas are not lower. The concept of supplier-induced demand (also known as Roemer's Law) was established back in the early 1960s [24, 25] . Given the argumentation above, high medication use might actually be a sound investment. Third, unlike some previous research, we find no relationship either between the level of smoking and costs, gender and costs, or comorbidity (except asthma) and costs. It seems that lung function and dyspnoea are such strong predictors of costs that they largely eliminate the influence of other factors. This leads us to the final, and most interesting, finding of this study: dyspnoea is a very strong cost driver. Earlier research has shown that the severity of COPD increases costs [3, [9] [10] [11] 23] . However, what has not been established in the previous literature is that suffering from severe dyspnoea adds even more costs to patients with severe COPD. Treatments that prevent severe dyspnoea thus have a high potential to be cost-effective in addition to improving QoL. More studies are required to confirm this.
The present paper also contributes to the methodological literature of COPD costs in several respects. Earlier research has identified a number of factors that may affect the costs of COPD. However, a few multivariate analyses of COPD costs has been carried out [12] . We have added a few more potential explanatory factors to the current literature and have applied stateof-the-art econometrics to examine this research question.
In an extensive sensitivity analysis we also explored a number of measurement and specification issues. On a methodological note, it is interesting to see the differences between the univariate regression analysis in Table 2 and the multiple regression analyses in Tables 3  and 4 . Our multivariate method eliminated a number of variables previously considered to affect COPD costs when analysed in a univariate way. This study has also shown that different types of costs are affected by slightly different factors.
While we believe our analysis and data offer advantages compared to previous studies, there are also important limitations. By optimal selection of the study sample, we have been able to show clear effects of various variables on COPD costs, although admittedly the sample size is relatively small. Furthermore, there is a large preponderance of costs located at zero. We corrected for the latter problem by also using alternative estimation techniques, although the results remained the same. With more data, our analysis could be further expanded by alternative methods of analysis, including taking better account of the large number of zero costs. Other limitations concern the fact that some variables that affect the COPD costs may have been omitted. This could be indicated by the explanatory power, ranging from 24% to 58%, for the six models. Furthermore, the collected resource use data can be considered out of date. While this may be true, no real breakthrough treatment for COPD has been launched since these data were recorded. So, while it is likely that the level of resource use today is likely to be different, we do not anticipate that the relationships between the variables have changed over time. Finally, the present analysis does not reflect disease progression as the study period was 12 months, although to some extent this is taken into account by including patients with severity ranging from very mild to severe.
In conclusion, the three dominant factors affecting the costs of COPD are poor lung function (FEV 1 ), asthma comorbidity and severe dyspnoea. These factors significantly increased all or most of the different components of costs. Strong efforts should be made to prevent the progression of COPD and its symptoms.
Foundation funded the population studies from which the COPD cohort was derived.
